AbbVie says ELAHERE-carboplatin trial in platinum-sensitive ovarian cancer posts 62.7% response rate

AbbVie, Inc.

AbbVie, Inc.

ABBV

0.00
  • AbbVie disclosed late-breaking Phase 2 results for ELAHERE (mirvetuximab soravtansine-gynx) in recurrent platinum-sensitive ovarian cancer.
  • Data was presented April 12 at Society of Gynecologic Oncology Annual Meeting 2026.
  • Trial showed strong tumor shrinkage outcomes with regimen combining ELAHERE with carboplatin, then continuing ELAHERE alone.
  • Responses held up in patients previously treated with PARP inhibitors, a group often harder to treat with repeat chemotherapy.
  • Safety profile remained broadly consistent with earlier ELAHERE studies, led by mostly manageable eye-related side effects.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AbbVie Inc. published the original content used to generate this news brief on April 12, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.